Targeting the SARS-CoV‑2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders

September 30, 2020

Haniff, H., Tong, Y., Liu, X., et al.

ACS Central Science 2020, vol: 6(10) doi: 10.1021/acscentsci.0c00984

Abstract

COVID-19 is a global pandemic, thus requiring multiple strategies to develop modalities against it. Herein, we designed multiple bioactive small molecules that target a functional structure within the SARS-CoV-2’s RNA genome, the causative agent of COVID-19. An analysis to characterize the structure of the RNA genome provided a revised model of the SARS-CoV-2 frameshifting element, in particular its attenuator hairpin. By studying an RNA-focused small molecule collection, we identified a drug-like small molecule (C5) that avidly binds to the revised attenuator hairpin structure with a Kd of 11 nM. The compound stabilizes the hairpin’s folded state and impairs frameshifting in cells. The ligand was further elaborated into a ribonuclease targeting chimera (RIBOTAC) to recruit a cellular ribonuclease to destroy the viral genome (C5-RIBOTAC) and into a covalent molecule (C5-Chem-CLIP) that validated direct target engagement and demonstrated its specificity for the viral RNA, as compared to highly expressed host mRNAs. The RIBOTAC lead optimization strategy improved the bioactivity of the compound at least 10-fold. Collectively, these studies demonstrate that the SARS-CoV-2 RNA genome should be considered druggable.

View Publication
 

Topics: PROTACs, Monolith – MicroScale Thermophoresis, MST,  Publications

 

 

 

Previous Article
Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay
Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay

Up next
Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA
Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA

Want to see more
PROTACs content?

Explore resources